Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:AARD

Aardvark Therapeutics Q4 2025 Earnings Report

Aardvark Therapeutics logo
$5.38 -0.35 (-6.11%)
As of 09/4/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Aardvark Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.81
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Aardvark Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aardvark Therapeutics Announcement Details

Quarter
Q4 2025
Date
3/23/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Aardvark Therapeutics' Q4 2025 Press ReleasePress Release
(8-K)
Aardvark Therapeutics' Q4 2025 Annual reportAnnual report
(10-K)

Aardvark Therapeutics Earnings Headlines

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD
September 5 at 12:34 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/05/3356883/673/en/rosen-a-global-and-leading-law-firm-encourages-aardvark-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-aard.html
AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
September 4 at 5:31 PM  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/09/04/10440824.htm
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
September 5 at 1:00 AM  |  Chaikin Analytics (Ad)
AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
September 4 at 5:21 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260904304659/en/aard-stockholders-have-rights-%e2%80%93-if-you-lost-money-investing-in-aardvark-therapeutics-inc.-contact-robbins-llp-for-information-about-recovering-your-losses/
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 4 at 10:09 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356623/0/en/aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law.html
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
September 3 at 5:31 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/aard-investor-notice-hagens-berman-alerts-investors-in-aardvark-therapeutics-nasdaq-aard-to-filing-of-securities-fraud-class-action-302869535.html
See More Aardvark Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aardvark Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aardvark Therapeutics and other key companies, straight to your email.

About Aardvark Therapeutics

Aardvark Therapeutics (NASDAQ:AARD) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders. Leveraging a proprietary screening platform, structural biology capabilities and medicinal chemistry expertise, Aardvark has advanced multiple preclinical candidates toward IND-enabling studies. These programs are supported by in vitro and in vivo pharmacology, biomarker development and toxicology assessments conducted at the company’s Cambridge research facilities.

Founded by a team of immunology and drug-development veterans, Aardvark Therapeutics is led by President and CEO Marshall Bolog, Ph.D. The leadership team combines translational pharmacology, clinical development and regulatory affairs expertise to guide the company’s pipeline through preclinical and early clinical stages. Aardvark pursues strategic collaborations with academic institutions and industry partners to enhance its RORγ portfolio and is positioned to advance its therapeutic candidates into human trials while exploring global licensing and development opportunities.

View Aardvark Therapeutics Profile
Earnings Tools